Compounded versions are not FDA-approved drug applications
Weekly dose of semaglutide 7.2 mg can significantly improve weight loss and related health outcomes in adults living with obesity owenhaskins Sep 15, 2025 2 min read A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults living with obesity, including those with type 2 diabetes (T2D), according to the results of two large-scale, international phase 3 clinical trials (STEP UP and STEP UP T2D clinical trials)
It is a suboptimal response that may still be clinically meaningful
A 2003 prospective cohort study by Khavinson and Morozov found that epithalon had the following effects when administered to a sample of 266 adults over the age of 60 [9]: Decreased incidence of ischemic heart disease Decreased incidence of hypertension disease Lowered rates of deforming osteoarthritis and osteoporosis More recently, a 2020 study by Khavinson et al
Thus, in a study whose objective was to determine the possible relation between the activity of the G6PD enzyme and the hypoxia, it was found that the hypoxia favored a decrease in its activity 27,28
